EXCLUSIVE PATENT LICENSE AGREEMENT by and between PURETECH VENTURES LLC and KARUNA PHARMACEUTICALS, INC.Exclusive Patent License Agreement • September 22nd, 2020 • PureTech Health PLC • Pharmaceutical preparations • Massachusetts
Contract Type FiledSeptember 22nd, 2020 Company Industry JurisdictionThis Agreement, effective as of the date set forth above the signatures of the parties below (the “Effective Date”), is between PureTech Ventures LLC, a Delaware limited liability company (“PureTech”), and Karuna Pharmaceuticals, Inc., a Delaware corporation (the “Company”). PureTech and the Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ROYALTY AGREEMENTRoyalty Agreement • September 22nd, 2020 • PureTech Health PLC • Pharmaceutical preparations • Massachusetts
Contract Type FiledSeptember 22nd, 2020 Company Industry JurisdictionThis ROYALTY AGREEMENT (the “Agreement”), dated as of July 23, 2013, is by and among (i) PureTech Ventures, LLC, a Delaware limited liability company (“PureTech”), and (ii) Follica, Incorporated, a Delaware corporation (the “Company”).
and- (ACTING AS AGENT FOR AND ON BEHALF OF ITS DISCRETIONARY MANAGED CLIENTS) RELATIONSHIP AGREEMENTRelationship Agreement • September 22nd, 2020 • PureTech Health PLC • Pharmaceutical preparations
Contract Type FiledSeptember 22nd, 2020 Company IndustryA Application has been made or will be made by the Company for all of the Ordinary Shares to be admitted to the Official List and to be admitted to trading on the main market for listed securities of the London Stock Exchange (“Admission”).
ROYALTY AND SUBLICENSE INCOME AGREEMENTRoyalty and Sublicense Income Agreement • September 22nd, 2020 • PureTech Health PLC • Pharmaceutical preparations • Delaware
Contract Type FiledSeptember 22nd, 2020 Company Industry JurisdictionThis ROYALTY ASSIGNMENT AGREEMENT (the “Agreement”), dated as of December 18, 2009, is by and among (i) PureTech Ventures, LLC, a Delaware limited liability company, (“PureTech”), (ii) Gelesis, Inc., a Delaware corporation, (“Gelesis-US”) and (iii) Gelesis LP (formerly AML-Dienstein B. V.), a Bermudan limited partnership (“Gelesis-Bermuda” and collectively with Gelesis-US, “Gelesis”).
ASSET PURCHASE AGREEMENT by and between AUSPEX PHARMACEUTICALS, INC. and PURETECH HEALTH LLC July 15, 2019Asset Purchase Agreement • September 22nd, 2020 • PureTech Health PLC • Pharmaceutical preparations • New York
Contract Type FiledSeptember 22nd, 2020 Company Industry JurisdictionThis ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 15, 2019 (the “Effective Date”), by and between AUSPEX PHARMACEUTICALS, INC., a Delaware corporation (“Auspex”) and PURETECH HEALTH LLC, a Delaware limited liability company (“Purchaser”).